Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.
2.

LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2.

Lu J, Chen M, Gao S, Yuan J, Zhu Z, Zou X.

Oncol Lett. 2018 Apr;15(4):4358-4364. doi: 10.3892/ol.2018.7843. Epub 2018 Jan 23.

3.

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, Chang L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34. doi: 10.1073/pnas.1014769108. Epub 2011 Feb 15.

4.

Small ubiquitin-like modifier 1 modification of pyruvate kinase M2 promotes aerobic glycolysis and cell proliferation in A549 human lung cancer cells.

An S, Huang L, Miao P, Shi L, Shen M, Zhao X, Liu J, Huang G.

Onco Targets Ther. 2018 Apr 13;11:2097-2109. doi: 10.2147/OTT.S156918. eCollection 2018.

5.

Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis.

Li H, Xu H, Xing R, Pan Y, Li W, Cui J, Lu Y.

Pathol Res Pract. 2019 Jun;215(6):152409. doi: 10.1016/j.prp.2019.04.001. Epub 2019 Apr 7.

PMID:
31000383
6.

HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells.

Huang L, Yu Z, Zhang T, Zhao X, Huang G.

PLoS One. 2014 Mar 21;9(3):e92949. doi: 10.1371/journal.pone.0092949. eCollection 2014.

7.

Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer.

Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, Cho JY.

World J Gastroenterol. 2012 Aug 14;18(30):4037-43. doi: 10.3748/wjg.v18.i30.4037.

8.

Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.

Dong T, Yan Y, Chai H, Chen S, Xiong X, Sun D, Yu Y, Deng L, Cheng F.

Biomed Pharmacother. 2015 Feb;69:277-84. doi: 10.1016/j.biopha.2014.12.010. Epub 2014 Dec 19.

PMID:
25661370
9.

Identification of small molecule inhibitors of pyruvate kinase M2.

Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC.

Biochem Pharmacol. 2010 Apr 15;79(8):1118-24. doi: 10.1016/j.bcp.2009.12.003. Epub 2009 Dec 11.

10.

PKM2 and cancer: The function of PKM2 beyond glycolysis.

Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, Jiang F.

Oncol Lett. 2016 Mar;11(3):1980-1986. Epub 2016 Jan 29.

11.

MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer.

Tang R, Yang C, Ma X, Wang Y, Luo D, Huang C, Xu Z, Liu P, Yang L.

Oncotarget. 2016 Feb 2;7(5):5972-84. doi: 10.18632/oncotarget.6821.

12.

Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice.

Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, Wang XH, Mu B, Wang W, Ma Y, Guo FC, Wei YQ.

Cancer Sci. 2010 Jun;101(6):1447-53. doi: 10.1111/j.1349-7006.2010.01562.x. Epub 2010 Mar 15. Erratum in: Cancer Sci. 2010 Jun;101(6):1575.

13.

MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1.

Sugiyama T, Taniguchi K, Matsuhashi N, Tajirika T, Futamura M, Takai T, Akao Y, Yoshida K.

Cancer Sci. 2016 Dec;107(12):1767-1775. doi: 10.1111/cas.13091. Epub 2016 Dec 19.

14.

Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect.

Wiese EK, Hitosugi T.

Front Cell Dev Biol. 2018 Jul 24;6:79. doi: 10.3389/fcell.2018.00079. eCollection 2018. Review.

15.

Follicle-stimulating hormone promoted pyruvate kinase isozyme type M2-induced glycolysis and proliferation of ovarian cancer cells.

Li S, Ji X, Wang R, Miao Y.

Arch Gynecol Obstet. 2019 May;299(5):1443-1451. doi: 10.1007/s00404-019-05100-4. Epub 2019 Feb 26.

PMID:
30809696
16.

Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo.

Meng MB, Wang HH, Guo WH, Wu ZQ, Zeng XL, Zaorsky NG, Shi HS, Qian D, Niu ZM, Jiang B, Zhao LJ, Yuan ZY, Wang P.

Cancer Lett. 2015 Jan 28;356(2 Pt B):985-93. doi: 10.1016/j.canlet.2014.11.016. Epub 2014 Nov 13.

PMID:
25444918
17.

Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.

Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe R, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Dec 15;12(12):1101-13. doi: 10.4161/cbt.12.12.18703. Epub 2011 Dec 15.

18.

Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.

Shankar Babu M, Mahanta S, Lakhter AJ, Hato T, Paul S, Naidu SR.

PLoS One. 2018 Feb 2;13(2):e0191419. doi: 10.1371/journal.pone.0191419. eCollection 2018.

19.

Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2.

Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, Wang Q.

Int J Mol Med. 2012 Aug;30(2):302-8. doi: 10.3892/ijmm.2012.989. Epub 2012 May 9.

PMID:
22580449
20.

Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.

Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, Kim HC, Hahm KB.

Clin Cancer Res. 2004 Dec 15;10(24):8687-96.

Supplemental Content

Support Center